These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38151901)

  • 1. Patient perspectives on factors influencing active surveillance adherence for low-risk prostate cancer: A qualitative study.
    Subramanian L; Hawley ST; Skolarus TA; Rankin A; Fetters MD; Witzke K; Chen J; Radhakrishnan A
    Cancer Med; 2024 Jan; 13(1):e6847. PubMed ID: 38151901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancer.
    Makarov DV; Sedlander E; Braithwaite RS; Sherman SE; Zeliadt S; Gross CP; Curnyn C; Shedlin M
    Implement Sci; 2016 Sep; 11(1):118. PubMed ID: 27590603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer.
    Radhakrishnan A; Subramanian L; Rankin AJ; Fetters MD; Wittmann DA; Ginsburg KB; Hawley ST; Skolarus TA
    Ann Fam Med; 2024; 22(1):5-11. PubMed ID: 38253492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of physician-patient relationships is associated with the influence of physician treatment recommendations among patients with prostate cancer who chose active surveillance.
    Orom H; Homish DL; Homish GG; Underwood W
    Urol Oncol; 2014 May; 32(4):396-402. PubMed ID: 24332649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.
    Kinsella N; Stattin P; Cahill D; Brown C; Bill-Axelson A; Bratt O; Carlsson S; Van Hemelrijck M
    Eur Urol; 2018 Sep; 74(3):261-280. PubMed ID: 29598981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient and disease factors affecting the choice and adherence to active surveillance.
    Dall'Era MA
    Curr Opin Urol; 2015 May; 25(3):272-6. PubMed ID: 25692724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
    van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
    BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
    Ellis SD; Hwang S; Morrow E; Kimminau KS; Goonan K; Petty L; Ellerbeck E; Thrasher JB
    BMC Cancer; 2021 May; 21(1):649. PubMed ID: 34058998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.
    Pang K; Fitch M; Ouellet V; Chevalier S; Drachenberg DE; Finelli A; Lattouf JB; So A; Sutcliffe S; Tanguay S; Saad F; Mes-Masson AM
    BMC Health Serv Res; 2018 Jun; 18(1):430. PubMed ID: 29884180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that influence clinicians' decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study.
    Lowenstein LM; Choi NJ; Hoffman KE; Volk RJ; Loeb S
    BMJ Open; 2021 Nov; 11(11):e048347. PubMed ID: 34772748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.
    Goh AC; Kowalkowski MA; Bailey DE; Kazer MW; Knight SJ; Latini DM
    BJU Int; 2012 Jul; 110(2 Pt 2):E50-6. PubMed ID: 22145791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active surveillance for low-risk localized prostate cancer: what do men and their partners think?
    Mallapareddi A; Ruterbusch J; Reamer E; Eggly S; Xu J
    Fam Pract; 2017 Feb; 34(1):90-97. PubMed ID: 28034917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review.
    Rittenmeyer L; Huffman D; Alagna M; Moore E
    JBI Database System Rev Implement Rep; 2016 Feb; 14(2):174-255. PubMed ID: 27536798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.
    Fitch M; Pang K; Ouellet V; Loiselle C; Alibhai S; Chevalier S; Drachenberg DE; Finelli A; Lattouf JB; Sutcliffe S; So A; Tanguay S; Saad F; Mes-Masson AM
    BMC Urol; 2017 Oct; 17(1):98. PubMed ID: 29078772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reported factors influencing the decision-making process of men with localised prostate cancer when considering Active Surveillance-A systematic review and thematic synthesis.
    Cunningham M; Murphy M; Sweeney P; Richards HL
    Psychooncology; 2022 Mar; 31(3):388-404. PubMed ID: 34605104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertainty.
    Mader EM; Li HH; Lyons KD; Morley CP; Formica MK; Perrapato SD; Irwin BH; Seigne JD; Hyams ES; Mosher T; Hegel MT; Stewart TM
    BMC Urol; 2017 May; 17(1):35. PubMed ID: 28482875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Living with untreated prostate cancer: predictors of quality of life.
    Bellardita L; Villa S; Valdagni R
    Curr Opin Urol; 2014 May; 24(3):311-7. PubMed ID: 24637318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
    Guan A; Santiago-Rodríguez EJ; Chung BI; Shim JK; Allen L; Kuo MC; Lau K; Loya Z; Brooks JD; Cheng I; DeRouen MC; Frosch DL; Golden T; Leppert JT; Lichtensztajn DY; Lu Q; Oh D; Sieh W; Wadhwa M; Cooperberg MR; Carroll PR; Gomez SL; Shariff-Marco S
    BMC Cancer; 2023 Dec; 23(1):1191. PubMed ID: 38053037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
    Brooks JV; Ellis SD; Morrow E; Kimminau KS; Thrasher JB
    Am J Mens Health; 2018 Sep; 12(5):1719-1727. PubMed ID: 29973123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-Based Assessment of Determining Treatments for Prostate Cancer.
    Chamie K; Williams SB; Hu JC
    JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.